Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. announced that its CEO, Scott Plesha, will present and hold one-on-one investor meetings at the 2026 Jefferies Global Healthcare Conference on June 4, 2026, in New York. The biopharmaceutical company focuses on commercializing innovative therapeutic products for unmet patient needs, including its lead product ZELSUVMI for molluscum contagiosum, and recently acquired XEPI for impetigo and XEGLYZE for head lice. The company aims to leverage its existing commercial infrastructure for these new product launches.

Pelthos Therapeutics Inc. announced that its CEO, Scott Plesha, will present at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:05 am ET in New York. He will also engage in one-on-one investor meetings. Pelthos is a biopharmaceutical company focused on cutaneous infectious disease products, with ZELSUVMI as its lead product for molluscum contagiosum, and other products like XEPI and XEGLYZE in its portfolio.

Pelthos Therapeutics Inc. formalized the separation terms for its former Chief Financial Officer, Treasurer, and Secretary, Francis Knuettel II, who was terminated effective April 10, 2026. The Separation Agreement, executed on May 15, 2026, includes a severance payment of $430,000 and accelerated vesting of certain stock options and restricted stock units. Concurrently, the company dismissed CBIZ CPAs P.C. as its independent registered public accounting firm and appointed Grant Thornton LLP for the fiscal year ending December 31, 2026, noting no disagreements with the former auditor.

Pelthos Therapeutics announced its first quarter 2026 financial results, reporting ZELSUVMI net product revenue of $10.7 million, a 17% increase quarter-over-quarter. The company also saw a 25% rise in ZELSUVMI units dispensed and expanded its sales force. Net loss significantly improved to $(10.2) million from $(21.7) million in the previous quarter, partly due to a gain from the change in fair value of convertible debt. Pelthos highlighted its $32.0 million cash balance and plans for future product launches.

Pelthos Therapeutics Inc. presented its corporate overview, highlighting its commercial biopharmaceutical focus on growing cutaneous infections products. The company emphasized its synergistic product acquisitions, including Xepi (launched July 2025) and Xeglyze (expected late 2026 launch), leveraging existing commercial infrastructure. Pelthos also noted strong potential revenue streams and a disciplined acquisition model, with a third product targeting 6-12 million U.S. cases annually slated for a first-half 2027 launch.

Pelthos Therapeutics Inc. presented its corporate overview, highlighting its focus as a commercial biopharmaceutical company on a growing, differentiated cutaneous infections product portfolio. The company emphasized its synergistic product acquisitions, Xepi and Xeglyze, which leverage existing commercial infrastructure. Pelthos anticipates strong potential revenue streams and outlined plans for new product launches in late 2026 and the first half of 2027, targeting significant addressable markets.

Pelthos Therapeutics Inc. announced that CEO Scott Plesha will engage in one-on-one investor meetings at the Piper Sandler Spring Biopharma Symposium on April 16, 2026. This participation provides an opportunity for the company to connect with potential investors and discuss its commercial-stage biopharmaceutical portfolio, which includes ZELSUVMI for Molluscum contagiosum, Xepi for impetigo, and Xeglyze for head lice. Such engagements are crucial for investor relations and raising company visibility within the biopharma sector.

Pelthos Therapeutics Inc. announced the promotion of John M. Gay to Chief Financial Officer, effective April 10, 2026. Mr. Gay previously held the position of Senior Vice President, Finance & Accounting. In his new role, he will report directly to the Chief Executive Officer and will receive an annual base salary of $425,000, along with eligibility for annual bonuses.

Pelthos Therapeutics Inc. announced the appointment of John M. Gay as its new Chief Financial Officer, effective April 10, 2026. Mr. Gay, who previously served as the company's Senior Vice President, Finance & Accounting since 2025, succeeds Francis Knuettel II. He brings over 25 years of public company finance and accounting experience to the role.